Effectiveness of Influenza A Vaccine May Be Diminished in Patients With MPNs
Researchers report on status of immune response to influenza A vaccination, particularly memory cell clusters, in patients with myeloproliferative neoplasms.
Researchers report on status of immune response to influenza A vaccination, particularly memory cell clusters, in patients with myeloproliferative neoplasms.
Incidence rate ratio 0.12 among women vaccinated before age 17; 0.47 for those vaccinated at ages 17 to 30.
Reluctance, fear to leave home may impact the amount of people willing to receive the flu vaccine this year.
Vaccination should be routinely offered at age 9 to 12 years; catch-up vaccination recommended through age 26.
Improvements in initiation and completion extend beyond conclusion of the intervention.
About a dozen potential vaccines worldwide are in the initial stages of, or set to begin, testing in people.
Practical implications of this study include the importance of encouraging patients with cancer considering ICI therapy to undergo influenza vaccination.
Educational videos produced the highest rate of acceptability and knowledge.
A retrospective study sought to determine if incidence or severity of irAEs was affected by the seasonal influenza vaccine in patients undergoing immunotherapy.
Researchers explored the feasibility of integrating pharmacists into the oncology care team for older patients with cancer to determine the impact this intervention would have on medication management and vaccination uptake.